Mazières B, Loyau G, Menkès C J, Valat J P, Dreiser R L, Charlot J, Masounabe-Puyanne A
Centre Hospitalier Universitaire, Toulouse.
Rev Rhum Mal Osteoartic. 1992 Jul-Sep;59(7-8):466-72.
One hundred twenty patients with osteoarthritis of the knees and hips were entered into a randomized, placebo-controlled, double-blind trial designed to evaluate the effectiveness of chondroitin sulfate (Structum). The three-month treatment phase was followed by a two-month treatment-free phase to allow evaluation of carry-over effects. The main endpoint was use of nonsteroidal antiinflammatory drugs (expressed as mg of diclofenac equivalent). At completion of the three-month treatment phase, patients taking chondroitin sulfate (4 capsules/day) were using significantly less NSAIDs; this decrease persisted throughout the two-month treatment-free follow-up phase. The other parameters studied including visual analog scale assessment of pain, the Lequesne pain-function index, and overall patient and physician assessments, all showed a similar significant tendency. Tolerance was outstanding and no patients required premature withdrawal. These findings indicate that chondroitin sulfate is useful for the treatment of osteoarthritis, both as an agent slowly effective against symptoms and to reduce the need for NSAIDs. The carry-over effect of the drug suggests that intermittent administration may be appropriate.
120名膝部和髋部骨关节炎患者参与了一项随机、安慰剂对照、双盲试验，旨在评估硫酸软骨素（Structum）的疗效。三个月的治疗阶段之后是两个月的无治疗阶段，以评估药物的残留效应。主要终点是使用非甾体抗炎药（以双氯芬酸当量毫克表示）。在三个月治疗阶段结束时，服用硫酸软骨素（每日4粒胶囊）的患者使用的非甾体抗炎药显著减少；在为期两个月的无治疗随访阶段，这种减少一直持续。研究的其他参数，包括疼痛的视觉模拟量表评估、Lequesne疼痛功能指数以及患者和医生的总体评估，均显示出类似的显著趋势。耐受性良好，没有患者需要提前退出试验。这些发现表明，硫酸软骨素可用于治疗骨关节炎，既作为一种对症状起效缓慢的药物，又能减少对非甾体抗炎药的需求。药物的残留效应表明间歇性给药可能是合适的。
